



▶ Screening for osteoporosis is in your hands.

MetriScan® from Alara, Inc.® ...

...was developed as a front line diagnostic tool to help physicians detect osteoporotic bone loss.

MetriScan is a self-contained desktop peripheral scanner that brings the power of osteoporosis screening into the primary care arena. For the first time in your office, you can screen for one of the key risk factors of osteoporotic fractures—low bone mineral density (BMD). And you can perform the test as quickly and easily as you currently check blood pressure.

Osteoporosis—the underdiagnosed disease

The results of a recent JAMA study¹ involving over 200,000 postmenopausal women over age 50 point to an urgent need for in-office screening for low bone mineral density (BMD). The three year JAMA study found osteoporosis woefully underdiagnosed by primary care physicians.

► **The Alara MetriScan Bone Density System gives you the power to screen patients at risk for osteoporosis — while they're in your office.**

Lack of diagnosis and the correlation between low BMD and fracture have serious implications for the over-50 postmenopausal woman. Clinically low BMD is directly linked to an increased risk of fracture within one year of diagnosis. And while over-50 women are the most underdiagnosed group for low BMD, many of your patients, both male and female, currently can and will suffer the same BMD-related fractures.

MetriScan can change all that with a simple two minute procedure.

You can estimate a patient's bone density during a routine check-up.

The Alara MetriScan system estimates bone density by taking a radiographic absorptiometry scan of the patient's hand. In no more than two minutes, MetriScan estimates the phalangeal bone density of the patient's three middle fingers. MetriScan compares the patient's BMD against the average estimated bone density of a healthy young adult female Caucasian population (T-score) and an age-matched healthy population of the patient's gender and ethnicity (Z-score). With the patient's data in the system, MetriScan then calculates the patient's T and Z scores and prints the test results for your analysis.

Early detection allows better treatment.

When your in-office routine involves testing at-risk patients, you'll be better able to detect and treat low BMD before an osteoporotic fracture occurs. With the variety of FDA-approved therapies for the treatment of osteoporosis, your at-risk patient population could have a far lower risk of disabling bone fractures. This early detection device also allows you to monitor the effectiveness of your prescribed course of osteoporosis treatment. From the very first scan of your patient's fingers, Alara MetriScan provides the data you need to better treat your patients.

1 ►
Input patient data



0:10 min
elapsed time

2 ►
Scan Fingers



0:11 min
elapsed time

3 ►
Calculate and display
T and Z scores



1:00 min
elapsed time




4 ►
Print results



2:00 min
elapsed time

Phalangeal Bone Density Predicts Hip Fractures²

The study correlated T-scores with hip fracture rates after correcting for age, weight and previous fractures



In a recent independent study of fourteen different methods of osteoporosis bone density testing², radiographic absorptiometry of the phalanges correlated with other measures as well as or better than any other measurement.

MetriScan features include:

- * less than one second scan
- * radiation dose less than 5% of dental x-ray
- * total clinical precision error = 1% vs. ultrasound systems (1.5% - 2.0%)
- * no gel or patient preparation required
- * automatic calibration check
- * small footprint: 16" x 16"

Scanning has been mandated a reimbursable expense.

Since the passage of the Bone Mass Measurement Act of 1997, Medicare coverage of biannual bone density testing has made testing a more affordable and more effective treatment option for your at-risk patient population. Medicare and most private insurers cover biannual bone density testing for the following patients:

- * Estrogen deficient women at risk for osteoporosis
- * Men or women with vertebral abnormalities indicative of osteoporosis
- * Men or women receiving long term steroid therapy
- * Men or women with primary hyperparathyroidism
- * Men or women being monitored to assess the response to osteoporosis drug therapy

MetriScan screening will become routine for your staff.

After a brief in-office tutorial, a practitioner can easily begin MetriScan screening of patients. It's a self-contained desktop unit, with an intuitive interface that makes it easy for staff to input basic patient data. Unlike other screening systems that require messy gels or cumbersome equipment, the Alara MetriScan is easy to administer. It's also painless for the patient, takes up minimal office space and exposes patients to minimal radiation.




► **When it comes to detecting low bone mineral density and preventing osteoporotic fractures, early detection is in your hands.**

For an in-office Alara MetriScan demonstration, or for technical/leasing information, please call us at 1-510-315-5200 or visit www.alara.com.

ALARA, Inc.
47505 Seabridge Drive
Fremont, CA 94538
1-510-315-5200
www.alara.com

© 2007 Alara and MetriScan are trademarks of Alara, Inc.

Class I Laser Product
203-0173-00 REV. B



1. E.S. Siris, et al. Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women. JAMA, December 12, 2001
2. Grampp, et al. Journal of Bone and Mineral Research, 12: 1997: 697-711
3. Mussolino, M., et al. Arch Intern Med, 1997; 157: 433-438.

